Literature DB >> 15056658

Oligomerization of wild type and nonfunctional mutant angiotensin II type I receptors inhibits galphaq protein signaling but not ERK activation.

Jakob Lerche Hansen1, Juliane Theilade, Stig Haunsø, Søren P Sheikh.   

Abstract

The 7-transmembrane or G protein-coupled receptors relay signals from hormones and sensory stimuli to multiple signaling systems at the intracellular face of the plasma membrane including heterotrimeric G proteins, ERK1/2, and arrestins. It is an emerging concept that 7-transmembrane receptors form oligomers; however, it is not well understood which roles oligomerization plays in receptor activation of different signaling systems. To begin to address this question, we used the angiotensin II type 1 (AT(1)) receptor, a key regulator of blood pressure and fluid homeostasis that in specific context has been described to activate ERKs without activating G proteins. By using bioluminescence resonance energy transfer, we demonstrate that AT(1) receptors exist as oligomers in transfected COS-7 cells. AT(1) oligomerization was both constitutive and receptor-specific as neither agonist, antagonist, nor co-expression with three other receptors affected the bioluminescence resonance energy transfer 2 signal. Furthermore, the oligomerization occurs early in biosynthesis before surface expression, because we could control AT(1) receptor export from the endoplasmic reticulum or Golgi by using regulated secretion/aggregation technology (RPD trade mark ). Co-expression studies of wild type AT(1) and AT(1) receptor mutants, defective in either ligand binding or G protein and ERK activation, yielded an interesting result. The mutant receptors specifically exerted a dominant negative effect on Galpha(q) activation, whereas ERK activation was preserved. These data suggest that distinctly active conformations of AT(1) oligomers can couple to each of these signaling systems and imply that oligomerization plays an active role in supporting these distinctly active conformations of AT(1) receptors.

Mesh:

Substances:

Year:  2004        PMID: 15056658     DOI: 10.1074/jbc.M400092200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  22 in total

1.  Deconvolution of complex G protein-coupled receptor signaling in live cells using dynamic mass redistribution measurements.

Authors:  Ralf Schröder; Nicole Janssen; Johannes Schmidt; Anna Kebig; Nicole Merten; Stephanie Hennen; Anke Müller; Stefanie Blättermann; Marion Mohr-Andrä; Sabine Zahn; Jörg Wenzel; Nicola J Smith; Jesús Gomeza; Christel Drewke; Graeme Milligan; Klaus Mohr; Evi Kostenis
Journal:  Nat Biotechnol       Date:  2010-08-15       Impact factor: 54.908

Review 2.  International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli [corrected].

Authors:  Sadashiva S Karnik; Hamiyet Unal; Jacqueline R Kemp; Kalyan C Tirupula; Satoru Eguchi; Patrick M L Vanderheyden; Walter G Thomas
Journal:  Pharmacol Rev       Date:  2015-10       Impact factor: 25.468

Review 3.  Monitoring the formation of dynamic G-protein-coupled receptor-protein complexes in living cells.

Authors:  Kevin D G Pfleger; Karin A Eidne
Journal:  Biochem J       Date:  2005-02-01       Impact factor: 3.857

4.  Transgenic expression of an altered angiotensin type I AT1 receptor resulting in marked modulation of vascular type I collagen.

Authors:  Jun Yu; Linda Taylor; Celeste Rich; Paul Toselli; Philip Stone; Daniel Green; Rod Warburton; Nicholas Hill; Ronald Goldstein; Peter Polgar
Journal:  J Cell Physiol       Date:  2012-05       Impact factor: 6.384

5.  Follice-stimulating hormone receptor forms oligomers and shows evidence of carboxyl-terminal proteolytic processing.

Authors:  Richard M Thomas; Cheryl A Nechamen; Joseph E Mazurkiewicz; Marco Muda; Stephen Palmer; James A Dias
Journal:  Endocrinology       Date:  2007-02-01       Impact factor: 4.736

6.  Differential Contribution of Transmembrane Domains IV, V, VI, and VII to Human Angiotensin II Type 1 Receptor Homomer Formation.

Authors:  Brent M Young; Elaine Nguyen; Matthew A J Chedrawe; Jan K Rainey; Denis J Dupré
Journal:  J Biol Chem       Date:  2017-01-17       Impact factor: 5.157

7.  Cardiac-specific overexpression of AT1 receptor mutant lacking G alpha q/G alpha i coupling causes hypertrophy and bradycardia in transgenic mice.

Authors:  Peiyong Zhai; Mitsutaka Yamamoto; Jonathan Galeotti; Jing Liu; Malthi Masurekar; Jill Thaisz; Keiichi Irie; Eric Holle; Xianzhong Yu; Sabina Kupershmidt; Dan M Roden; Thomas Wagner; Atsuko Yatani; Dorothy E Vatner; Stephen F Vatner; Junichi Sadoshima
Journal:  J Clin Invest       Date:  2005-11       Impact factor: 14.808

8.  Distinctive Activation Mechanism for Angiotensin Receptor Revealed by a Synthetic Nanobody.

Authors:  Laura M Wingler; Conor McMahon; Dean P Staus; Robert J Lefkowitz; Andrew C Kruse
Journal:  Cell       Date:  2019-01-10       Impact factor: 41.582

9.  Rab1 GTPase and dimerization in the cell surface expression of angiotensin II type 2 receptor.

Authors:  Xiaoping Zhang; Guansong Wang; Denis J Dupré; Yumei Feng; Mélanie Robitaille; Eric Lazartigues; Ying-Hong Feng; Terence E Hébert; Guangyu Wu
Journal:  J Pharmacol Exp Ther       Date:  2009-04-08       Impact factor: 4.030

10.  Complement factor 5a receptor chimeras reveal the importance of lipid-facing residues in transport competence.

Authors:  Jeffery M Klco; Saurabh Sen; Jakob L Hansen; Christina Lyngsø; Gregory V Nikiforovich; Soren P Sheikh; Thomas J Baranski
Journal:  FEBS J       Date:  2009-05       Impact factor: 5.542

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.